Prostate small cell carcinoma
MONDO:0006390A neuroendocrine carcinoma of the prostate gland with unfavorable prognosis, composed of small cells containing neurosecretory granules. Approximately half of the cases show a mixture of small cells and adenocarcinoma cells.
Also known as: Oat cell carcinoma of prostate, Oat cell carcinoma of the prostate, prostate Oat cell carcinoma, prostate gland small cell carcinoma, prostate oat cell carcinoma, prostate small cell NEC, prostate small cell carcinoma, prostate small cell neuroendocrine carcinoma
2780 clinical trials for this condition and its sub-types, 9 tagged with Prostate small cell carcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New combo therapy aims to tame tough prostate cancer
Disease control OngoingThis phase 2 trial tests a multi-drug approach for men with aggressive variant prostate cancer that has spread. First, patients receive chemotherapy (cabazitaxel and carboplatin) plus an immunotherapy (cetrelimab). Then, they are randomly assigned to take either a PARP inhibitor …
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Can a three-drug cocktail outsmart resistant prostate cancer?
Disease control OngoingThis phase 2 trial is testing whether combining three drugs—ZEN-3694, enzalutamide, and pembrolizumab—can shrink tumors or lower PSA levels in men with metastatic castration-resistant prostate cancer that has worsened despite prior treatment. ZEN-3694 blocks a protein that fuels …
Phase 2 • Sponsor: Rahul Aggarwal • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New drug cocktail targets tough prostate cancer
Disease control OngoingThis study tests a combination of four drugs (nivolumab, ipilimumab, cabazitaxel, and carboplatin) in 41 men with a hard-to-treat form of prostate cancer. The goal is to see if this mix can slow or stop cancer growth. Participants receive up to 10 cycles of the combo, then contin…
Phase 2 • Sponsor: Andrew J. Armstrong, MD • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Immunotherapy-Chemo combo targets tough neuroendocrine cancers
Disease control OngoingThis early-phase trial tests whether adding the immunotherapy drug pembrolizumab to standard platinum-based chemotherapy can help people with rare, aggressive small cell or neuroendocrine cancers of the bladder or prostate. The study includes 15 participants whose cancer has spre…
Phase 1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC